STRATA Skin Sciences, Inc.

DB:E2O Stock Report

Market Cap: €13.1m

STRATA Skin Sciences Past Earnings Performance

Past criteria checks 0/6

STRATA Skin Sciences's earnings have been declining at an average annual rate of -24.6%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 5% per year.

Key information

-24.6%

Earnings growth rate

-23.0%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate5.0%
Return on equity-87.6%
Net Margin-25.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How STRATA Skin Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:E2O Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2433-8221
31 Mar 2433-11231
31 Dec 2333-11231
30 Sep 2335-7241
30 Jun 2336-7251
31 Mar 2337-6261
31 Dec 2236-6251
30 Sep 2235-6251
30 Jun 2233-6251
31 Mar 2231-3231
31 Dec 2130-3231
30 Sep 2128-2211
30 Jun 2126-3202
31 Mar 2122-6181
31 Dec 2023-4171
30 Sep 2025-4181
30 Jun 2027-4191
31 Mar 2031-3221
31 Dec 1932-4221
30 Sep 1931-3211
30 Jun 1931-3211
31 Mar 1931-3201
31 Dec 1830-4191
30 Sep 1831-9201
30 Jun 1830-22191
31 Mar 1831-21192
31 Dec 1732-22192
30 Sep 1730-18172
30 Jun 1731-6182
31 Mar 1730-4192
31 Dec 1631-3202
30 Sep 1633-3232
30 Jun 1633-14243
31 Mar 1626-22222
31 Dec 1518-28192
30 Sep 159-34152
30 Jun 151-24111
31 Mar 151-15111
31 Dec 141-16112
30 Sep 141-14112
30 Jun 141-19132
31 Mar 140-27143
31 Dec 131-26164
30 Sep 131-27165

Quality Earnings: E2O is currently unprofitable.

Growing Profit Margin: E2O is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: E2O is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.

Accelerating Growth: Unable to compare E2O's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: E2O is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.2%).


Return on Equity

High ROE: E2O has a negative Return on Equity (-87.55%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/03 23:49
End of Day Share Price 2024/06/06 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

STRATA Skin Sciences, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory ChodaczekBoenning & Scattergood, Inc.
Jose De Jesus HarescoBrean Capital
null nullCG Capital